Core Insights - The agricultural chemical sector experienced a significant increase of 3.69% on November 13, with Xin'an Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4029.5, up 0.73%, while the Shenzhen Component Index closed at 13476.52, up 1.78% [1] Agricultural Chemical Sector Performance - Xin'an Co., Ltd. (600596) closed at 12.39, with a rise of 10.04% and a trading volume of 807,400 shares, amounting to a transaction value of 991 million [1] - Salt Lake Co., Ltd. (000792) saw a closing price of 26.89, increasing by 7.95% with a trading volume of 1,840,800 shares, totaling 4.88 billion [1] - Hebang Bio (603077) closed at 2.41, up 7.11%, with a trading volume of 7,137,700 shares, resulting in a transaction value of 1.71 billion [1] - Other notable performers included Yuntu Holdings (002539) with a 6.68% increase, and Xingfa Group (600141) with a 6.54% rise [1] Capital Flow Analysis - The agricultural chemical sector saw a net inflow of 1.425 billion in main funds, while retail investors experienced a net outflow of 1.31 billion [2] - The main funds' net inflow for Xin'an Co., Ltd. was 182 million, representing 18.35% of its trading volume [3] - Salt Lake Co., Ltd. had a net inflow of 197 million, accounting for 4.04% of its trading volume [3] - In contrast, retail investors withdrew 1.12 billion from Xin'an Co., Ltd., indicating a significant divergence in investor sentiment [3]

Group 1 - The core viewpoint is that Hebang Bio's glyphosate products, produced using the IDA process, have higher purity and fewer impurities compared to domestic competitors, providing a competitive advantage despite higher unit costs [2]. Group 2 - Hebang Bio confirmed on the investor interaction platform that their glyphosate products utilize the IDA process, which results in better quality [2]. - The company acknowledged that while the quality of their glyphosate products is superior, the unit cost of the IDA process is higher than that of other domestic glycine routes [2].

Core Viewpoint - The stock of Hebang Biotechnology has shown a positive trend with a year-to-date increase of 12.75%, reflecting investor interest and market activity [1][2]. Group 1: Stock Performance - On November 7, Hebang Biotechnology's stock rose by 2.22%, reaching 2.30 CNY per share, with a trading volume of 2.18 billion CNY and a turnover rate of 1.09%, resulting in a total market capitalization of 203.12 billion CNY [1]. - The stock has experienced a 5.50% increase over the last five trading days, a 2.22% increase over the last 20 days, and a 22.34% increase over the last 60 days [1]. - Year-to-date, the stock has appeared on the "Dragon and Tiger List" once, with a net buy of 50.22 million CNY on October 9, contributing to a total buy of 229 million CNY, which accounted for 13.21% of total trading volume [1]. Group 2: Company Overview - Hebang Biotechnology, established on August 1, 2002, and listed on July 31, 2012, is located in Leshan, Sichuan Province, and specializes in the manufacturing of pesticides, fine chemicals, and various glass products [2]. - The company's revenue composition includes 85.89% from chemical products, 17.61% from photovoltaic glass and other products, 6.74% from mineral products, and 5.02% from other businesses [2]. - As of September 30, 2025, the company reported a revenue of 5.927 billion CNY, a year-on-year decrease of 13.02%, and a net profit attributable to shareholders of 93.11 million CNY, down 57.93% year-on-year [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Hebang Biotechnology was 196,500, a decrease of 1.99% from the previous period, with an average of 44,939 shares held per shareholder, an increase of 2.03% [2]. - The top ten circulating shareholders include new entrants such as Penghua CSI Sub-Segment Chemical Industry Theme ETF and Everbright Prudential Credit Enhanced Bond A, indicating a shift in institutional holdings [3].

1. Report Industry Investment Rating No relevant content provided. 2. Core View of the Report The report presents the top ten convertible bonds for November 2025, along with an analysis of the issuing companies, including their financial performance, business models, and key attractions [14][23][36]. 3. Summary by Company 3.1 Zhongte Convertible Bond - Issuer: A globally leading specialized special steel material manufacturing enterprise with a production capacity of approximately 20 million tons of special steel materials per year [14]. - Financial Performance: In 2024, its operating income was 109.203 billion yuan (YoY -4.22%), and the net profit attributable to the parent company was 5.126 billion yuan (YoY -10.41%). In the first three quarters of 2025, the operating income was 81.206 billion yuan (YoY -2.75%), and the net profit attributable to the parent company was 4.33 billion yuan (YoY +12.88%) [14]. - Key Attractions: It is one of the world's steel companies with the most comprehensive variety and specifications, with a production capacity of over 20 million tons of special steel. It has a complete industrial chain, leading cost - control capabilities, and is seeking opportunities for external expansion [15]. 3.2 Shanlu Convertible Bond - Issuer: A company mainly engaged in road and bridge engineering construction and maintenance, with a complete business and management system [23]. - Financial Performance: In 2024, its operating income was 71.348 billion yuan (YoY -2.3%), and the net profit attributable to the parent company was 2.322 billion yuan (YoY +1.47%). In the first three quarters of 2025, the operating income was 41.354 billion yuan (YoY -3.11%), and the net profit attributable to the parent company was 1.41 billion yuan (YoY -3.27%) [23]. - Key Attractions: It has the concept of "China - Special Valuation," potential for improvement in its balance sheet and order volume. It can benefit from infrastructure construction in Shandong Province and the Belt and Road Initiative [26]. 3.3 Hebang Convertible Bond - Issuer: A company with advantages in salt mines, phosphate mines, and natural gas supply, covering the chemical, agricultural, and photovoltaic sectors [36]. - Financial Performance: In 2024, its operating income was 8.547 billion yuan (YoY -3.13%), and the net profit attributable to the parent company was 31 million yuan (YoY -97.55%). In the first three quarters of 2025, the operating income was 5.927 billion yuan (YoY -13.02%), and the net profit attributable to the parent company was 93 million yuan (YoY -57.93%) [36]. - Key Attractions: Its phosphate mines and salt mines contribute to profits, and its liquid methionine production has high - margin potential [37]. 3.4 Aima Convertible Bond - Issuer: A leading enterprise in the electric two - wheeler industry, responsible for R & D, production, and sales [45]. - Financial Performance: In 2024, its operating income was 21.606 billion yuan (YoY +2.71%), and the net profit attributable to the parent company was 1.988 billion yuan (YoY +5.68%). In the first three quarters of 2025, the operating income was 21.093 billion yuan (YoY +20.78%), and the net profit attributable to the parent company was 1.907 billion yuan (YoY +22.78%) [45]. - Key Attractions: The continuation of government subsidies for trade - ins, the implementation of new national standards, and potential improvements in gross margin [46]. 3.5 Xingye Convertible Bond - Issuer: One of the first joint - stock commercial banks approved by the State Council and the People's Bank of China, evolving into a modern financial service group [56]. - Financial Performance: In 2024, its operating income was 212.226 billion yuan (YoY +0.66%), and the net profit attributable to the parent company was 77.205 billion yuan (YoY +0.12%). In the first three quarters of 2025, the operating income was 161.234 billion yuan (YoY -1.82%), and the net profit attributable to the parent company was 63.083 billion yuan (YoY +0.12%) [56]. - Key Attractions: Stable asset quality and continuous growth in scale [57]. 3.6 Huanxu Convertible Bond - Issuer: A global leader in electronic manufacturing design, providing value - added services [67]. - Financial Performance: In 2024, its operating income was 60.691 billion yuan (YoY -0.17%), and the net profit attributable to the parent company was 1.652 billion yuan (YoY -15.16%). In the first three quarters of 2025, the operating income was 43.641 billion yuan (YoY -0.83%), and the net profit attributable to the parent company was 1.263 billion yuan (YoY -2.6%) [67]. - Key Attractions: Leading in smart wearable SiP modules and having a global production layout [68]. 3.7 Chongyin Convertible Bond - Issuer: The earliest local joint - stock commercial bank in the upper reaches of the Yangtze River and Southwest China, with a wide range of business operations [79]. - Financial Performance: In 2024, its operating income was 13.679 billion yuan (YoY +3.54%), and the net profit attributable to the parent company was 5.117 billion yuan (YoY +3.8%). In the first three quarters of 2025, the operating income was 11.74 billion yuan (YoY +10.4%), and the net profit attributable to the parent company was 4.879 billion yuan (YoY +10.19%) [79]. - Key Attractions: Benefiting from the Chengdu - Chongqing economic circle strategy, stable asset growth, and proactive risk management [80]. 3.8 Tianye Convertible Bond - Issuer: A leading enterprise in the chlor - alkali chemical industry in Xinjiang, with an integrated circular economy industrial chain [88]. - Financial Performance: In 2024, its operating income was 11.156 billion yuan (YoY -2.7%), and the net profit attributable to the parent company was 68 million yuan (YoY +108.83%). In the first three quarters of 2025, the operating income was 7.97 billion yuan (YoY +2.2%), and the net profit attributable to the parent company was 7 million yuan (YoY -28.79%) [88]. - Key Attractions: Relatively stable caustic soda production costs and plans to increase dividend frequency and advance coal mine projects [89]. 3.9 Aorui Convertible Bond - Issuer: A company focusing on the R & D, production, and sales of complex APIs and preparations, leading in multiple fields [101]. - Financial Performance: In 2024, its operating income was 1.476 billion yuan (YoY +16.89%), and the net profit attributable to the parent company was 355 million yuan (YoY +22.59%). In the first three quarters of 2025, the operating income was 1.237 billion yuan (YoY +13.67%), and the net profit attributable to the parent company was 354 million yuan (YoY +24.58%) [101]. - Key Attractions: Improving its dealer network, expanding the market for its preparation products, and having high - quality customer resources [102]. 3.10 Yushui Convertible Bond - Issuer: The largest integrated water supply and drainage enterprise in Chongqing, with a monopoly position in the local market [110]. - Financial Performance: In 2024, its operating income was 6.999 billion yuan (YoY -3.52%), and the net profit attributable to the parent company was 785 million yuan (YoY -27.88%). In the first three quarters of 2025, the operating income was 5.568 billion yuan (YoY +7.21%), and the net profit attributable to the parent company was 779 million yuan (YoY +7.1%) [110]. - Key Attractions: Stable water supply and drainage business, expanding market share, and effective cost control [111].

Group 1 - The core viewpoint of the news is that Hebang Biotechnology (603077.SH) has reported its Q3 2025 results, highlighting significant institutional investor holdings [1] - As of October 28, 2025, a total of 10 institutional investors hold shares in Hebang Biotechnology, with a combined holding of 2.823 billion shares, representing 31.97% of the company's total equity [1] - The top ten institutional investors include notable entities such as Sichuan Hebang Investment Group Co., Ltd. and Huatai Securities Co., Ltd., with their combined holding ratio increasing by 0.27 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, the Chemical ETF, increased its holdings by 0.95% compared to the previous period [2] - One public fund, the Southern CSI 500 ETF, reported a slight decrease in holdings [2] - Five new public funds were disclosed this period, including E Fund Credit Benefit Bond A and others, while 140 public funds were not disclosed this period, including several CSI 500 ETFs [2]

Core Viewpoint - The company has announced adjustments to its production capacity in response to customer demand for glyphosate products, increasing the production scale of its Indonesian project from 200,000 tons/year to 350,000 tons/year while pausing the implementation of a sodium carbonate and ammonium chloride project due to regulatory delays [8][10][11]. Financial Data - The third-quarter financial report for 2025 has been approved by the board, confirming the accuracy and completeness of the financial information presented [2][7]. - The financial statements for the first nine months of 2025 are unaudited, with the company confirming that there are no significant changes in its financial condition or operational results [3][6]. Shareholder Information - The company has disclosed that it holds or has joint ventures in 41 mineral resources, with only 2 salt mining rights currently in production [5][11]. Investment Progress - The company has been actively communicating with potential customers to align production with market demand, leading to the decision to convert the entire 500,000 tons/year dual glyphosate production into glyphosate [10][11]. - The adjustment in production capacity is part of the company's strategy to enhance competitiveness in the glyphosate sector and is supported by ongoing technological innovations and process optimizations [11]. Project Impact - The capacity adjustment is expected to lower overall investment costs and operational risks without significantly impacting the company's financial status or core business operations [11].

Core Insights - The company reported a revenue of 5.927 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 13.02% [1] - The net profit attributable to shareholders was 93.11 million yuan, down 57.93% year-on-year [1] - The net profit after deducting non-recurring items was 89.69 million yuan, reflecting a decrease of 58.35% year-on-year [1] - The basic earnings per share stood at 0.0117 yuan [1]

Core Viewpoint - Hebang Biotechnology (603077.SH) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The total operating revenue for the first three quarters reached 5.927 billion yuan, representing a year-on-year decrease of 13.02% [1] - The net profit attributable to shareholders was 93.1085 million yuan, down 57.93% year-on-year [1] - The basic earnings per share were 0.0117 yuan [1]

证券代码：603077 证券简称：和邦生物 公告编号：2025-048 债券代码：113691 债券简称：和邦转债 四川和邦生物科技股份有限公司 注 3：营养剂及中间体、副产品包括：蛋氨酸、甲硫醇钠、硫酸铵等； 注 4：上述统计数据中：产量不包含内部领用部分，销量不包含内部销售部分。 二、主要产品和原材料价格（不含税）变动情况 （一）主要产品价格（不含税）变动情况 2025年1-9月公司主要化工产品价格变动情况如下： 2025 年 1-9 月主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上市公司自律监管指引第 3 号行业信息披露：第十三 号——化工》及相关要求，四川和邦生物科技股份有限公司（以下简称"公司"） 现将 2025 年 1-9 月主要经营数据披露如下： 一、主要产品的产量、销量及收入实现情况 | 主要产品 | 产量（吨） | 销量（吨） | 营业收入（万元） | | --- | --- | --- | --- | | 联碱化工类产品 | 1,339,705.53 | 931,3 ...

| 证券代码：603077 | 证券简称：和邦生物 | 公告编号：2025-049 | | --- | --- | --- | | 债券代码：113691 | 债券简称：和邦转债 | | 三、本次调整印尼项目产能对公司的影响 四川和邦生物科技股份有限公司 对外投资进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资概述 四川和邦生物科技股份有限公司（以下简称"公司"）分别于 2023 年 8 月 30 日、2024 年 8 月 9 日在上海证券交易所网站（http://www.sse.com.cn）及指 定信披媒体披露了《和邦生物关于签署<合作投资意向书>等的公告》及《和邦生 物对外投资进展公告》，就公司投资印尼项目的具体情况和进展进行了披露。 二、对外投资进展情况 经公司通过与潜在客户不断的沟通交流，为充分响应客户对我司草甘膦产品 的需求，决定将广安年产 50 万吨双甘膦产品全部制成草甘膦。为匹配前述调整， 公司计划将印尼项目中的草甘膦生产规模从20万吨/年调整到35万吨/年。同时， 印尼项目中计划实施的 ...